A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.
about
Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells.Compliance of a cobalt chromium coronary stent alloy--the COVIS trialApolipoprotein J: A New Predictor and Therapeutic Target in Cardiovascular Disease?Late thrombosis associated with drug-eluting stentsClopidogrel in acute coronary heart diseaseLate acute thrombosis after implantation of sirolimus-eluting stent to treat in-stent restenosisThe safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart diseaseDual antiplatelet therapy and drug eluting stents: a marriage of convenienceGuidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of CardiologyCompliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study.Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual?Triggers, targets and treatments for thrombosis.Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells.Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques.Blockade of TGF-β by catheter-based local intravascular gene delivery does not alter the in-stent neointimal response, but enhances inflammation in pig coronary arteries.The disutility of restenosis--the impact of repeat percutaneous coronary intervention on quality of life.Endothelialization and in-stent restenosis on the surface of glycoprotein IIIa monoclonal antibody eluting stent.3,3'Diindolylmethane suppresses vascular smooth muscle cell phenotypic modulation and inhibits neointima formation after carotid injury.Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis.Stem cell treatment of the heart: a review of its current status on the brink of clinical experimentationCost-effectiveness of drug-eluting vs. bare-metal stents in patients with coronary artery disease from the Korean National Health Insurance DatabaseThe multifunctional Ca2+/calmodulin-dependent kinase II delta (CaMKIIdelta) controls neointima formation after carotid ligation and vascular smooth muscle cell proliferation through cell cycle regulation by p21.The relationship between re-endothelialization and endothelial function after DES implantation: comparison between paclitaxcel eluting stent and zotarolims eluting stentAre "treatment" bare metal stents superior to "control" bare metal stents? A meta-analytic approachRevascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting.A prospective, multi-centric, observational registry to evaluate performance of Excel™ DES in 'real world, all comers' patient population.Vascular endothelial growth factor-bound stents: application of in situ capture technology of circulating endothelial progenitor cells in porcine coronary model.Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives.First human trial of KW39 slotted-tube stents: for percutaneous coronary interventionPercutaneous coronary interventions with drug eluting stents for diabetic patientsEfficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials.Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study.On-label and off-label use of drug-eluting stents: comparison of short- and long-term outcomesArterial stiffness in patients with coronary artery disease: relation with in-stent restenosis following percutaneous coronary intervention.Decision models for assessing the cost effectiveness of drug-eluting stents.Update on drug-eluting coronary stents.Drug eluting stents: an updated meta-analysis of randomised controlled trialsEffectiveness of Two-Year versus One-Year Use of Dual Antiplatelet Therapy in Reducing the Risk of Very Late Stent Thrombosis after Drug-Eluting Stent Implantation.Recent advances in adult cardiac surgery.A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease.
P2860
Q24815293-8555A801-0BDC-48F8-A823-A6B677481DEBQ24816753-0602166D-7D94-4C24-BF6B-2D82CE1C0F83Q26781196-7F43903B-E4AC-4594-B473-75B218462EE9Q28188113-2D85802A-4E1C-48C2-9D71-F6116FB8EB74Q28193776-0C1EE1D4-B24D-4F76-8787-53DE660D8A9AQ28199944-3EAEBBC4-2575-4DCA-A875-860E516454E3Q28200757-0BE3BC76-09E7-4DD1-98AF-F18EB3A77226Q28222394-EEF45D43-002F-498D-92E0-50A645227277Q28239975-4AE1A358-4044-49EE-9CD0-2D7555669184Q30476674-3796761A-7DCA-4A1F-820C-85875B70094CQ33553921-91D53AAA-03B3-4C8B-8833-0AA5CF010EC2Q33765444-19B09298-E3FF-4A5F-A6A3-31F862F62B1FQ33776274-23F5615C-4AB6-40A4-89F9-FE11E3270D66Q33839384-F7565BC4-A872-4425-B145-DB676DA857AAQ33909025-38DC9516-799A-499B-98D6-50A22A31F0A8Q33994074-46208086-55DB-4674-B1E2-9D7CE0DC2B98Q34177967-ABA92E18-B9D0-426F-BAB7-7F8BFAD82FEBQ34233778-FE096E9A-CF5C-427E-8C61-5EE5C320EECEQ34256787-BA96B76E-35BD-4892-9DC3-0927E21A4777Q34315088-E36C6CCA-047A-4A2F-8E77-71B217B5746DQ34384310-CC708067-6152-4A68-AD93-DD5DFFDDB733Q34624215-440CE575-39E0-4DEB-B958-BD87865EC05DQ34669858-F7FB9A75-786F-4E75-9893-0E3C6A290906Q34731151-A0D84BA5-C2DA-4972-B279-8ABD5672E1FBQ34793647-4E73328E-D4E0-4572-93D3-9A649948B17FQ35028661-2ADA5E53-7579-4F82-90A2-52B83AF963E8Q35079541-9CFF80BF-CC06-4A5D-8D6E-A5F782286D3FQ35193488-223B6468-F997-4113-8915-A4C33475A71AQ35594750-2A4B6798-68CC-49F7-81C2-6536DD20DAE1Q35771445-B31DC61D-7C0C-4B91-BDD3-980A6955E1F3Q35771807-FDB264DA-8E0C-4188-A9BE-11A9D833EC84Q35771937-ECC3C8A1-BBF2-4DEA-BEAB-B1E607D6784CQ35820167-9511238F-11C4-409E-A7B1-9BCAD20E9C2AQ36041966-1E824CAA-ADA0-4B7E-A0B6-C07F9658222AQ36161276-61F9C8E5-7C8E-44F7-AECA-2222C20B473BQ36266053-21DBBC28-F904-4515-A310-E35A6082E26DQ36282710-C8B453F7-DE31-45A8-BCBF-C076E370F743Q36305145-E3B5D7C9-C751-4AC8-B55F-A867D785785FQ36471473-C6226434-99F6-404E-9323-39E5942936B0Q36488244-C0412274-1800-4864-9386-5A62632528B1
P2860
A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
A hierarchical Bayesian meta-a ...... trials of drug-eluting stents.
@en
A hierarchical Bayesian meta-a ...... trials of drug-eluting stents.
@nl
type
label
A hierarchical Bayesian meta-a ...... trials of drug-eluting stents.
@en
A hierarchical Bayesian meta-a ...... trials of drug-eluting stents.
@nl
prefLabel
A hierarchical Bayesian meta-a ...... trials of drug-eluting stents.
@en
A hierarchical Bayesian meta-a ...... trials of drug-eluting stents.
@nl
P2093
P1433
P1476
A hierarchical Bayesian meta-a ...... trials of drug-eluting stents.
@en
P2093
Lawrence Joseph
Mark J Eisenberg
Mohan N Babapulle
Patrick Bélisle
P304
P356
10.1016/S0140-6736(04)16850-5
P407
P577
2004-08-01T00:00:00Z